Tarsus Pharmaceuticals, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -19.59 | -100% |
| P/S |
|
33.95 | 33.76 | 0.5773% |
|
|
| P/BV |
|
3.01 | 4.82 | -37.62% |
|
|
| P/FCF |
|
-4.54 | 61 | -107.44% |
|
|
| Ev/Ebitda |
|
-2.81 | -22.15 | -87.34% |
|
|
| Ev/S |
|
22.88 | 22.56 | 1.39% |
|
|
| Ev/FCF |
|
-3.25 | 68.78 | -104.72% |
|
|
| E/P |
|
-0.2434 | 0.0178 | -1469.44% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-815.5 | 4.98 | -16485.66% | -270.08 | +201.95% |
| ROE |
|
-68.99 | 9.61 | -817.73% |
|
|
| ROA |
|
-51.04 | 0.3443 | -14927.37% |
|
|
| ROIC |
|
-25.09 | 7.63 | -428.65% |
|
|
| ROS |
|
-778.89 | -25.17 | 2994.5% |
|
|
| ROCE |
|
-72.67 | 15.35 | -573.43% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.2124 | -3.68 | -94.22% | -0.2008 | +5.76% |
| Nеt Debt/Ebitda |
|
1.36 | -3.44 | -139.51% |
|
|
| Debt/Ratio |
|
0.1135 | 0.1985 | -42.82% |
|
|
| Debt/Equity |
|
31.57 | 1.66 | 1799.53% |
|
|
| Debt/Net Income |
|
-0.2224 | 10.32 | -102.15% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5468 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.2632 | -100% | ||
| DSI |
|
0 | 0.2193 | -100% |
|
|
| Average dividend growth |
|
0 | 0.4414 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4968 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5468 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
-47.76 | -56.89 | -16.05% | ||
| Growth impulse Ebitda in 5 years |
|
3276.15 | -54.68 | -6091.5% | ||
| Growth impulse Net Income in 5 years |
|
2617.86 | -58.33 | -4588.02% | ||
| Growth impulse FCF in 5 years |
|
2974.88 | -49.48 | -6112.29% | ||
| Growth impulse EPS in 5 years |
|
133.58 | -32.41 | -512.16% |
IP Score
3.92/10
